



OPEN ACCESS

The cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysis

Gina A. Smith*, Gareth W. Fearnley*, Darren C. Tomlinson*, Michael A. Harrison† and Sreenivasan Ponnambalam*¹

*School of Molecular & Cellular Biology, University of Leeds, Leeds LS2 9JT, U.K.

†School of Biomedical Sciences, University of Leeds, Leeds LS2 9JT, U.K.

Synopsis

VEGFs (vascular endothelial growth factors) are a family of conserved disulfide-linked soluble secretory glycoproteins found in higher eukaryotes. VEGFs mediate a wide range of responses in different tissues including metabolic homeostasis, cell proliferation, migration and tubulogenesis. Such responses are initiated by VEGF binding to soluble and membrane-bound VEGFRs (VEGF receptor tyrosine kinases) and co-receptors. VEGF and receptor splice isoform diversity further enhances complexity of membrane protein assembly and function in signal transduction pathways that control multiple cellular responses. Different signal transduction pathways are simultaneously activated by VEGFR–VEGF complexes with membrane trafficking along the endosome–lysosome network further modulating signal output from multiple enzymatic events associated with such pathways. Balancing VEGFR–VEGF signal transduction with trafficking and proteolysis is essential in controlling the intensity and duration of different intracellular signalling events. Dysfunction in VEGF-regulated signal transduction is important in chronic disease states including cancer, atherosclerosis and blindness. This family of growth factors and receptors is an important model system for understanding human disease pathology and developing new therapeutics for treating such ailments.

Key words: disease, drugs, isoforms, membrane trafficking, receptor tyrosine kinase, signal transduction, vascular endothelial growth factor (VEGF).

Cite this article as: Bioscience Reports (2015) 35, e00253, doi:10.1042/BSR20150171

INTRODUCTION

The VEGF (vascular endothelial growth factor) superfamily and its receptors are highly conserved in metazoan species [1]. In lower eukaryotes, such as worms and flies, a hybrid PDGF (platelet-derived growth factor) and VEGF system of ligands and receptors mediates a range of biological responses. Many of the VEGF genes and receptors play essential roles in animal development and function. However, a recurring theme is the subversion of VEGF ligand and receptor function in a range of pathologies including cancer, atherosclerosis, AMD (age-related macular degeneration) and pre-eclampsia. In the present review, we will consider how ligand and receptor diversity underpins complexity

in signal transduction, membrane trafficking and proteolysis with implications for normal and pathophysiological states.

VEGF DIVERSITY AND FUNCTIONALITY

The VEGF superfamily consists of five structurally-related members of angiogenic and lymphangiogenic polypeptides: VEGF-A, VEGF-B, VEGF-C, VEGF-D and PlGF (placental growth factor). These growth factors are highly conserved with subtle differences in the distribution of charged residues determining receptor

Abbreviations: Akt, protein kinase B; AMD, age-related macular degeneration; CBL, Cas-BR-M murine ecotropic retroviral transforming sequence homologue; DAG, diacylglycerol; eNOS, endothelial nitric oxide synthase; ERK1/2, extracellular signal-regulated kinase 1/2; FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; Fln, fms-related tyrosine kinase; Fyn, Fyn proto-oncogene, Src family tyrosine kinase; Grb2, growth factor receptor-bound protein 2; HDAC, histone deacetylase; HSP, heat shock protein; HS, heparan sulfate; HSPG, heparan sulfate glycoprotein; IP₃, inositol-1,4,5-trisphosphate; MAPK, mitogen-activated protein kinase; Nck, Nck adaptor protein 1; NO, nitric oxide; NRP, neuropilin; PDCL3, phosphoducin-like 3; PDGF, platelet-derived growth factor; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C; PLC γ 1, phospholipase C γ 1; PlGF, placental growth factor; PTP, protein tyrosine phosphatase; Rab, Ras-associated protein; RCC, renal cell carcinoma; RTK, receptor tyrosine kinase; Shb, SH2-domain-containing adaptor protein B; sVEGFR, soluble VEGFR; TACE, tumour necrosis factor α converting enzyme; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor tyrosine kinase.

¹ To whom correspondence should be addressed (email s.ponnambalam@leeds.ac.uk).




Figure 1 Structural differences between VEGF-A, PlGF and VEGF-C determine VEGFR binding

(A) Ribbon diagram depicting the structural similarities between VEGF-A (blue; PDB ID: 3V2A), PlGF (green; PDB ID: 1RV6) and VEGF-C (cyan; PDB ID 4BSK). (B) A model of VEGF-A binding to VEGFR2 using the PlGF dimer as a template for VEGF-A binding to the Ig-like domains. (C) Structures of VEGF-A (top), PlGF (middle) and VEGF-C (bottom) reveal that although the fundamental fold is similar, the distribution of hydrophobic (purple) and polar (cyan) residues highlights differences between VEGFR1-binding ligands, VEGF-A and PlGF and VEGFR3-binding ligand, VEGF-C. (D) Structures of VEGF-A (top), PlGF (middle) and VEGF-C (bottom) rotated 90° with positive (blue), negative (red), aliphatic (yellow) and aromatic (purple) residues highlighted. (E) Structures of VEGF-A (top), PlGF (middle) and VEGF-C (bottom) rotated 90° with positive (blue) and negative (red) residues highlighted.

binding specificity (Figure 1). VEGFs regulate blood and lymph vessel development in an isoform-specific manner through activation of class III receptor tyrosine kinases (VEGFRs): VEGFR1 [Flt-1 (fms-related tyrosine kinase 1)], VEGFR2 [KDR (kinase insert domain receptor)] and VEGFR3 (Flt-4) [2]. VEGF polypeptides form homodimers but heterodimers of VEGF-A and PlGF also occur [3]. Complexity in the VEGF family is heightened by alternative splicing of VEGF-A, VEGF-B and PlGF and proteolytic processing of VEGF-C and VEGF-D. This allows multiple protein isoforms with distinct receptor and extracellular matrix-binding properties to be encoded by a single gene [4]. Correct *VEGFA* gene dosage is essential for normal mammalian health and development. Heterozygous *VEGFA*^{+/-} knockout mice die between embryonic days E11 and E12 due to a deformed vascular network [5,6]. Dysfunction in the response to VEGF-A can cause pathological angiogenesis and play pivotal roles in chronic inflammatory diseases, ischaemic heart disease, cancer and retinopathy [7–9].

The human *VEGFA* gene encodes a pre-mRNA with at least eight exons and seven introns [10]. Alternative RNA splicing pro-

duces at least seven pro-angiogenic isoforms of human VEGF-A which encode polypeptides of 121, 145, 148, 165, 183, 189 or 206 residues (a isoforms) and five anti-angiogenic isoforms of 121, 145, 165, 183 and 189 residues denoted VEGF-A_{xxx}. Recent work has shown that *VEGFA* mRNA also undergoes programmed translational read-through to generate an anti-angiogenic VEGF-A_x isoform containing a unique 22 amino acid C-terminus extension [11]. Each VEGF-A isoform contains exons 1–5 which encode the signal sequence (exon 1), N-terminus dimerization domain (exon 2), VEGFR1-binding and N-glycosylation site (exon 3), VEGFR2-binding site (exon 4) and a plasmin cleavage site (exon 5). Exons 6a, 6b, 7a and 7b encode the heparin-binding domain and their variable inclusion significantly influences the biological properties of each VEGF-A isoform. Those isoforms containing exon 6a, such as VEGF-A₁₄₅ and VEGF-A₁₈₉, are weaker chemotactic cytokines and mitogens [12–14]. Exon 6a has a preponderance of basic amino acids which act to directly reduce VEGFR2–VEGF-A binding [15]. Interestingly, exon 6-containing isoforms do not inhibit VEGF-A-stimulated VEGFR1 activity and can promote VEGFR1-mediated vascular permeability [14,16].

Signal transduction and protein kinase activity is implicated in regulating proximal and distal splice site selection on the primary RNA, e.g. specifying the C-terminus six amino acids with either the pro-angiogenic CDKPRR (exon 8a) or anti-angiogenic SLTRKD (exon 8b) sequence [17]. The C-terminus SLTRKD sequence in the anti-angiogenic VEGF-A_{165b} isoform cannot bind the co-receptor, NRP1 (neuropilin 1), leading to an altered VEGFR2 protein complex which exhibits reduced tyrosine kinase activity [17]. Reduced co-receptor binding could explain the anti-angiogenic properties of VEGF-A_{165b} in combination with competition between VEGF-A_{165b} and pro-angiogenic VEGF-A_{165a} isoforms for binding to VEGFR2 [13,17]. Down-regulated VEGF-A_{165b} expression correlates with cellular switching to a pro-angiogenic phenotype that is associated with multiple pathologies including diabetic retinopathy and several adult epithelial cancers [18,19]. Conversely, up-regulated VEGF-A_{165b} expression in skin and circulatory tissues of patients with systemic sclerosis hinders angiogenesis and vascular repair [20].

Human *VEGFB* contains seven exons and encodes at least two isoforms with alternative splice acceptor sites present in exon 6 [21,22]. The VEGF-B₁₆₇ C-terminus contains the highly basic NRP1/heparin-binding domain whereas the more freely diffusible VEGF-B₁₈₆ isoform has a hydrophobic C-terminus which undergoes O-linked glycosylation and proteolytic processing [21].

Within the VEGF family, VEGF-C and VEGF-D are unique in being initially synthesized as precursor proteins containing long N- and C-terminal propeptides [23,24]. Proteolytic removal of both the N- and the C-propeptides releases mature, bioactive VEGF-D containing the central VEGF-homology domain. Such processing increases VEGF-D affinity for VEGFR3; furthermore, only mature VEGF-D binds VEGFR2 [25]. Although two mouse VEGF-D isoforms have been described [26], little is known about alternate RNA splicing of human VEGF-C and VEGF-D.

Four PlGF isoforms with distinct properties are encoded by the *PGF* gene. The most commonly expressed or major isoforms are

PlGF-1 (131 amino acids) and PlGF-2 (152 amino acids) [27]. The PlGF-2 exon 6 heparin-binding domain facilitates binding to heparin and NRP1. Contrastingly, PlGF-1 and PlGF-3 (203 amino acids) lack exon 6 so are unable to bind heparin [28]. PlGF-3 contains an additional 216 nt insertion between exons 4 and 5. PlGF-4 (224 amino acids) consists of the same sequence as PlGF-3 plus the exon 6-encoded heparin-binding domain [29]. These larger isoforms may function similarly to VEGF-A₁₈₉ and VEGF-A₂₀₆ [29].

Notably, crystal structures of VEGFs lack information on the C-terminal portion of these proteins (Figure 1). This raises important functional questions as to how binding by the VEGF carboxy proximal domain(s) 'programs' assembly of a functional signalling complex with different molecular partners recruited depending on the VEGF isoform and VEGFR involved.

VEGFs bind to the extracellular domain of VEGFRs and additional cell surface-expressed co-receptors, e.g. HSPGs (heparan sulfate glycoproteins), NRPs, integrins and ephrin B2 [30,31]. PlGF and VEGF-B specifically bind VEGFR1 and NRP1 whereas VEGF-A binds both VEGFR1 and VEGFR2 (Figure 2) [32–34]. VEGF-C and VEGF-D bind VEGFR2 and VEGFR3 (Figure 2) [35]. Distinct splice variants of VEGF-A assemble specific receptor–co-receptor complexes. Spatial and temporal aspects of VEGFR signal transduction can be influenced by the restricted diffusion of HS-binding VEGFs and is further modulated by VEGF interactions with the extracellular matrix [36]. Binding of VEGF-A_{165a} and VEGF-A₁₈₉ to HSPGs and NRP1 promotes ternary complex formation and VEGFR2 signal transduction. NRP1 binding to VEGF-A_{165a} enhances VEGFR2–VEGF-A_{165a} complex formation and tyrosine kinase activity. Optimal p38 MAPK (mitogen-activated protein kinase) activation is achieved through NRP1-enhanced VEGF-A_{165a} signal transduction [13]. In contrast, VEGF-A₁₂₁ is freely diffusible but NRP1 binding does not promote ternary complex formation with VEGFR2, causing reduced signal transduction [37]. Despite PlGF only binding VEGFR1, activation of VEGFR2 could occur indirectly through VEGF-A displacement from VEGFR1, thus increasing VEGF-A bioavailability for VEGFR2 [38]. Furthermore, PlGF/VEGF-A heterodimers can induce VEGFR1/VEGFR2 dimerization and downstream VEGFR2 activation [39].

The substantially different functions of VEGFR1-specific ligands, VEGF-B and PlGF, raise the possibility that VEGFR1 function is regulated by co-receptor recruitment and/or cell-specific intracellular signalling events [40]. VEGF-B-stimulated fatty acid synthesis in endothelial cells is crucial in organs which experience high metabolic stress, such as the heart, and involves both VEGFR1 and NRP1 activation [41]. Such therapeutic aspects are highlighted in cardiac endothelial cells where VEGF-B promotes physiological angiogenesis and revascularization of the ischaemic myocardium [42]. In contrast, PlGF expression is associated with cancer progression and required for inflammation-associated angiogenesis [38]. PlGF promotes pathological angiogenesis in several inflammatory disease states in which VEGFR1-regulated recruitment of bone marrow-derived monocytes precedes deposition of angiogenic growth factors [38]. Tumours that exhibit increased PlGF secretion sug-

gest a functional link between VEGFR1 activity and cancer progression.

VEGFR DIVERSITY AND FUNCTIONALITY

The RTK (receptor tyrosine kinase) subfamily containing VEGFRs is denoted as class V. These membrane-bound RTKs comprise VEGFR1, VEGFR2 and VEGFR3. VEGFRs exhibit structural and sequence homologies and comprise an extracellular ligand-binding domain consisting of seven Ig-like repeats, a transmembrane domain, a juxtamembrane domain, a split tyrosine kinase domain and a C-terminal tail.

VEGFR1

The *VEGFR1* gene contains 30 exons and encodes an estimated 151 kDa transmembrane receptor which undergoes post-translational modifications to produce a ~180 kDa mature glycoprotein [43,44]. VEGF-A has highest affinity for VEGFR1 [44] but the activated complex exhibits relatively weak tyrosine kinase activity and forms a non-productive signalling complex [10,45]. This poor tyrosine kinase activity of VEGFR1 is thought to arise from structural properties of the activation loop, a repressor sequence in its juxtamembrane domain and a lack of positive regulatory tyrosine residues [46–48]. VEGFR1 is expressed in various cell types including both quiescent and actively proliferating endothelial cells, haematopoietic stem cells, monocytes, macrophages and tumour cells [2,10,40]. VEGFR1 is essential for mammalian development as homozygous *VEGFR1*^{-/-} knockout mice die between embryonic days E8.5 and E9.5 after endothelial hyperproliferation leads to blood vessel obstruction [49]. The *VEGFR1* primary RNA transcript also undergoes alternative splicing to generate a soluble VEGFR1 isoform (sFlt-1; sVEGFR1) of ~110 kDa. This sVEGFR1 isoform comprises Ig-like domains 1–6 of the VEGFR1 ectodomain but also includes a unique 31 residue sequence (encoded by intron 13) at the C-terminus [50]. This sVEGFR1 can be a potent inhibitor of VEGF-A, VEGF-B and PlGF signal transduction [51]. In leukaemia cells, PlGF and VEGF-A induce tyrosine phosphorylation of VEGFR1 and increase ectodomain shedding. This occurs via PKC (protein kinase C) activation and metalloproteases such as TACE [tumour necrosis factor α (TNF α) converting enzyme] [52]. TACE activity generates sVEGFR1 and an intracellular cytoplasmic fragment; plasma membrane detachment of this cytoplasmic fragment requires γ -secretase/presenilin activity [53].

One view is that VEGFR1 has positive or negative regulatory roles in angiogenesis depending on biological conditions. A VEGFR1 negative regulatory role is thought to arise from sVEGFR1 acting as a decoy receptor to sequester VEGF-A away from VEGFR2 or by formation of non-signalling VEGFR1–VEGFR2 heterodimers [54]. A VEGFR1 positive regulatory role could occur under pathological conditions of tumour growth; here, abnormally high expression of VEGFR1-specific ligands leads to




Figure 2 Receptor tyrosine kinase subfamily of VEGFR proteins
Schematic illustrating interacting VEGF ligands, cytoplasmic phosphorylated tyrosine residues and functional outputs associated with each VEGFR upon VEGF binding. Ig-like domains mediate interaction between VEGFR monomers to promote complex assembly.

elevated VEGFR1 tyrosine kinase activity and promotes angiogenesis [55].

VEGFR2

Immature VEGFR2 has an estimated molecular mass of ~152 kDa and undergoes translocation to the endoplasmic reticulum and N-linked glycosylation along the secretory pathway to produce a mature glycoprotein with an approximate mass of 200–230 kDa [36,45]. Only mature fully glycosylated VEGFR2 undergoes efficient *trans*-autophosphorylation following VEGF stimulation [56]. Alternative splicing generates sVEGFR2, which is present in plasma, as well as in multiple tissues, including the heart, spleen, skin, ovary and kidney. This sVEGFR2 can sequester free VEGF-C, thus preventing VEGFR3 activation and inhibiting lymphatic endothelial cell proliferation [57]. VEGFR2 is essential for healthy mammalian development as homozygous *VEGFR2*^{-/-} knockout mice die at embryonic day E8.5, exhibiting impaired haematopoietic and endothelial cell development leading to formation of an insufficient vascular network [58]. This also mimics the *VEGFA*^{+/-} knockout mice phenotype [5,40,59].

VEGFR2 expression is predominantly restricted to endothelial cells and haematopoietic stem cell precursors, with peaks in expression during embryonic development [60].

VEGF-A binds VEGFR2 with a relatively high affinity ($K_d \sim 150$ pM); however, this parameter is ~10-fold lower than that for VEGFR1 ($K_d \sim 15$ pM) [61]. Nonetheless, the majority of VEGF-A-regulated angiogenesis effects are attributed to interaction with VEGFR2. One view is that VEGFR2 is a more potent tyrosine kinase which targets numerous substrates including membrane proteins, cytoplasmic enzymes and regulators [2,62]. VEGFR2 is thus considered to be the major pro-angiogenic switch which regulates blood vessel development and homeostasis in response to circulating VEGFs [2,62]. VEGFR2 expression is down-regulated in quiescent adult vascular network [63], probably reducing the magnitude of VEGFR2-regulated pro-angiogenic responses [64].

VEGFR3

VEGFR3 is an essential regulator of lymphoendothelial function and lymphangiogenesis. Upon co-translational insertion of

newly synthesized VEGFR3 into the endoplasmic reticulum, this ~195 kDa precursor protein undergoes N-linked glycosylation and proteolytic cleavage within the fifth Ig-like domain. This generates an N-terminal polypeptide which forms a stable disulfide linkage with the carboxy half of the VEGFR3 precursor [65]. VEGFR3 complexity is further increased by alternative splicing to produce both long and short isoforms [66,67]. The VEGFR3 short isoform lacks 65 residues proximal to the C-terminus; this is only present in humans and probably arose through a retroviral integration event during human speciation [68]. Furthermore, the VEGFR3 short isoform lacks two carboxy proximal cytoplasmic phosphorylation epitopes which are detected in VEGFR3 homodimers but not in VEGFR2–VEGFR3 heterodimers [69]. *VEGFR3*^{-/-} knockout mice die during embryogenesis between E10 to E11 caused by impaired hierarchical formation of the peripheral blood vasculature and defects in cardiac remodelling [70]. The role(s) of VEGFR3 in lymphatic endothelial cell responses is well-studied; however, VEGFR3 expression is also up-regulated in vascular endothelial cells during angiogenesis [40,71]. VEGFR3 expression is also detected in non-endothelial cells, such as macrophages, neuronal progenitors and osteoblasts, whereas its functional presence in tumours is much debated [40]. Mice expressing kinase-deficient VEGFR3 maintain normal physiological blood vessel development but exhibit impaired lymphatic development [72]. VEGFR3 mutations which perturb tyrosine kinase activity are associated with variants of hereditary lymphoedema, reinforcing the pivotal role of VEGFR3 in lymphatic endothelial cell function [73].

SIGNAL TRANSDUCTION

Most parenchymal cells express and secrete VEGF-like ligands such as VEGF-A. These ligands act in a paracrine manner on neighbouring endothelial cells to regulate VEGFR-mediated signal transduction and influence endothelial, lymphatic, epithelial and neural cell responses [1,74,75]. Notably, autocrine VEGF-A-induced signal transduction is considered essential for maintaining endothelial cell survival [76]. VEGF-stimulated signal transduction regulates a host of endothelial cell responses including proliferation, migration, permeability and cell–cell interactions.

Activation of the cytoplasmic tyrosine kinase domain by ligand-induced VEGFR2 homo- or heterodimerization causes conformational changes that expose the ATP-binding site within the tyrosine kinase domain [77]. The exchange of ADP for ATP initiates *trans*-autophosphorylation of key tyrosine residues on the receptor dimer which create docking sites for SH2-domain-containing signal adaptor molecules and trigger waves of intracellular signal transduction [78]. VEGFR tyrosine kinase activity is tightly regulated by ubiquitination, internalization, dephosphorylation and degradation by PTPs (protein tyrosine phosphatases) such as PTP1B and VE-PTP (vascular endothelial PTP) [79].

VEGFR1-regulated signal transduction

A highly postulated model is that VEGFR1 acts as a ‘VEGF trap’ [54]. Nonetheless, VEGF-A binding to VEGFR1 Ig-like domains 2 and 3 (Figure 1) can trigger relatively low levels of *trans*-autophosphorylation on specific VEGFR1 cytoplasmic tyrosine residues Tyr⁷⁹⁴, Tyr¹¹⁶⁹, Tyr¹²¹³, Tyr¹²⁴², Tyr¹³⁰⁹, Tyr¹³²⁷ and Tyr¹³³³ (Figure 2) [80–82]. Patterns of VEGFR1 tyrosine phosphorylation are ligand-dependent, e.g. VEGFR1-pY1309 epitope is caused by PlGF binding and linked to downstream activation of Akt (protein kinase B) and effects on cell physiology [83].

Computational modelling suggests VEGFR1–VEGFR2 heterodimers comprise 10%–50% of activated VEGFR complexes in response to VEGF-A; such modelling predicts low incidence of VEGFR1 homodimers when VEGFR2 levels are relatively high [84]. Functional coupling of VEGFR1 and VEGFR2 through heterodimerization and *trans*-autophosphorylation could modulate endothelial cell responses [36]. Surprisingly, transgenic mice bearing a modified *VEGFR1-TK*^{-/-} locus expressing a VEGFR1 truncated protein lacking tyrosine kinase activity are viable and exhibit normal blood vessel formation during development; however, such mice exhibit defects in VEGF-A-dependent macrophage migration [85]. Other studies on heterozygous *VEGFR1-TK*^{+/-} transgenic mice suggest that VEGFR1 tyrosine kinase activity is required for angiogenesis during tumour metastasis, in some inflammatory diseases, stroke, liver repair, gastric ulcer healing and various carcinomas and glioblastomas [85]. Although VEGFR1 is considered to be a ‘poor’ tyrosine kinase, therapeutics aimed at this RTK could be an attractive option for specific disease states [86].

VEGFR1 is functionally linked to endothelial cell migration and actin re-organization through RACK1 (receptor for activated C kinase 1) activation [87]. Additionally, activated VEGFR1 up-regulates uPA (urinary-type plasminogen activator) and PAI-1 (plasminogen activator inhibitor-1) levels which influence p38 MAPK regulation of actin dynamics, extracellular matrix degradation and cell migration [7,88]. VEGFR1-dependent activation of PI3K (phosphoinositide 3-kinase) is linked to endothelial cell proliferation and tubulogenesis [89]. Other targets of VEGFR1-mediated signal transduction include PLC γ 1 (phospholipase C γ 1), Grb2 (growth factor receptor-bound protein 2) and PTPN11 (PTP non-receptor type 11)/SHP2 (SH2 domain-containing tyrosine phosphatase 2) [48]. VEGFR1 activation produces the cytoplasmic pY1169 and pY794 epitopes that promote PLC γ 1 recruitment, leading to PIP₂ (phosphatidylinositol-4,5-bisphosphate) cleavage and production of DAG (diacylglycerol) and IP₃ (inositol-1,4,5-trisphosphate) [2,80]. IP₃ binding to the membrane-bound IP₃R (IP₃ receptor) in the endoplasmic reticulum facilitates Ca²⁺ ion translocation into the cytosol. One consequence of such activity is engagement of the calmodulin-calcineurin pathway which causes dephosphorylation of NFAT (nuclear factor of activated T-cells) family members leading to their activation, nuclear translocation and stimulation of gene transcription at specific loci [36]. This pro-angiogenic pathway promotes an inflammatory response [90]. VEGFR1-specific ligands such as PlGF and VEGF-B bind to monocytes and stimulate intracellular signalling events including ERK1/2

(extracellular signal-regulated kinase 1/2), Akt and p38 MAPK pathways [91].

VEGFR2-regulated signal transduction

VEGFR2-specific signal transduction influences endothelial proliferation, migration, survival and tubulogenesis. Ligand binding to the VEGFR2 extracellular domain triggers cytoplasmic tyrosine kinase activation and *trans*-autophosphorylation at residues Tyr⁸⁰¹, Tyr⁹⁵¹, Tyr¹⁰⁵⁴, Tyr¹⁰⁵⁹, Tyr¹¹⁷⁵, Tyr¹²¹⁴, Tyr¹²²³, Tyr¹³⁰⁵, Tyr¹³⁰⁹ and Tyr¹³¹⁹ (Figure 2). The VEGFR2-pY951 epitope provides a binding site for SH2 domain-containing TAd (T-cell-specific adaptor molecule) which is functionally linked to endothelial cell migration and vascular permeability [92]. Generation of the VEGFR2-pY1059 epitope enables recruitment of the proto-oncogene and soluble tyrosine kinase Src (proto-oncogene c-Src) which can further promote phosphorylation of residue Tyr¹¹⁷⁵. VEGFR2-pY1175 recruitment of PLC γ 1 causes DAG release and activation of PKC and MAPK enzymes (e.g. ERK1/2) which influence gene expression and cell proliferation [93]. Furthermore, VEGF-A stimulates both membrane and sVEGFR1 expression through VEGFR2 and PKC-dependent pathways [94]. VEGF-A-stimulated ERK1/2 activation leads to the hyperphosphorylation of ATF-2 (activating transcription factor 2), causing elevated expression of VCAM-1 (vascular endothelial cell adhesion molecule 1) and promoting endothelial-leucocyte interactions [95]; this now provides a MAPK-regulated gene expression mechanism that links angiogenesis and inflammation.

VEGFR2-pY1175 recruitment of PLC γ 1 and adaptor protein Shb (SH2-domain-containing adaptor protein B) facilitates interaction with FAK (focal adhesion kinase) and contributes to endothelial cell migration and attachment [96]. Shb activation of PI3K results in sequential activation of Akt and eNOS (endothelial nitric oxide (NO) synthase) which promote cell survival and NO-induced vascular permeability respectively [2,51]. The VEGFR2-pY1214 epitope recruits the adaptor protein Nck (Nck adaptor protein 1) and a cytoplasmic tyrosine kinase, Fyn (Fyn proto-oncogene, Src family tyrosine kinase) Nck-Fyn complex formation regulates phosphorylation of PAK2 (p21-activated protein kinase 2), which in turn activates Cdc42 (cell division cycle 42) and p38 MAPK [97]; impacting on cell migration through increased actin remodelling. VEGF-regulated PI3K activation mediates cell survival through sequential PDK1 (PI-dependent protein kinase 1) and Akt activation. Akt is a multi-functional regulator that can target BAD (Bcl-2-associated agonist of cell death) and caspase 9, thus blocking apoptosis [98].

Other post-translational modifications, such as methylation, are involved in VEGFR2 activation. VEGFR2 methylation takes place at multiple lysine and arginine residues, such as residue Leu¹⁰⁴¹ which is proximal to the kinase domain activation loop. Although methylation is ligand-independent, it enhances tyrosine phosphorylation and kinase activity in response to ligand [99]. In addition, VEGFR2 is acetylated at a dense cluster of four lysine residues in the kinase insert domain and at a single lysine within the kinase activation loop [100]. The acetyltransferase p300 and two deacetylases, histone deacetylase 5

(HDAC5) and HDAC6, regulate VEGFR2 acetylation in a process essential for controlling sustained ligand-dependent RTK *trans*-autophosphorylation and downstream signal transduction [100].

VEGFR3-regulated signal transduction

VEGF-C or VEGF-D binding to VEGFR3 stimulates tyrosine kinase activation and phosphorylation of VEGFR3 cytoplasmic domain residues Tyr⁸³⁰, Tyr⁸³³, Tyr⁸⁵³, Tyr¹⁰⁶³, Tyr¹⁰⁶⁸, Tyr¹²³⁰, Tyr¹²³¹, Tyr¹²⁶⁵, Tyr¹³³³, Tyr¹³³⁷ and Tyr¹³⁶³ (Figure 2) [69]. The VEGFR3-pY1063 epitope facilitates interaction with CRK I/II (adaptor protein C10 regulator of kinase) which in turn activates the JNK (c-Jun N-terminal kinase) pathway and promotes cell survival [101]. PI3K activation is crucial for lymphatic development by mediating lymphoendothelial migration [102]. Ligand-induced phosphorylation of VEGFR3 residues Tyr¹²³⁰ and Tyr¹²³² regulates cell migration, apoptosis and lymphoendothelial cell DNA synthesis [101]. The VEGFR3-pY1230 and -pY1232 epitopes recruit the Shc and Grb2 adaptor proteins which promote signal transduction through ERK1/2 and Akt/PI3K pathways which are important for lymphatic endothelial cell migration [101,103]. Formation of VEGFR2-VEGFR3 heterodimers is required for VEGF-C-induced Akt activation. In contrast, ERK1/2 is activated by VEGFR3 homodimers [103]. VEGFR2-VEGFR3 heterodimers are common in endothelial cells engaged in active angiogenesis, particularly at tip cell filopodia. Although VEGF-A does not bind VEGFR3, it is possible that VEGFR3 contributes to VEGF-A mediated blood vessel sprouting through heterodimer formation [77].

VEGFR TRAFFICKING AND TURNOVER

VEGFR1 was initially postulated solely as a plasma membrane resident RTK but work has revealed that ~80% is located within a stable pool in the Golgi apparatus along the secretory pathway [104]. VEGF-A stimulation of endothelial cells causes transient redistribution of VEGFR1 to the plasma membrane via a *trans*-Golgi network-to-plasma membrane route that is regulated by cytosolic calcium flux [104] (Figure 3). Calcium ion-regulated trafficking involves activation of VEGFR2 at the plasma membrane; this feedback model explains how VEGF-A-stimulated cellular responses are linked to VEGFR1 and VEGFR2 trafficking and turnover [105]. VEGFR1 levels are relatively insensitive to VEGF-A stimulation and endosome-lysosome trafficking, unlike VEGFR2 [88,104]. Activated VEGFR1 is internalized through clathrin-mediated endocytosis by ternary complex formation with CBL (Cas-Br-M murine ecotropic retroviral transforming sequence homologue) [106] and adaptor protein CD2AP (CD2-associated protein), followed by association with clathrin [107].

VEGFR2 is localized to the Golgi, plasma membrane, early endosomes and perinuclear caveolae in non-stimulated endothelial




Figure 3 VEGFR activation, trafficking and proteolysis

Schematic depicting ligand-activated VEGFR trafficking and proteolysis. Upon VEGFA binding, VEGFR2 undergoes dimerization, trans-autophosphorylation and ubiquitination. Following internalization into early endosomes, both activated and quiescent VEGFR2 can undergo recycling back to the plasma membrane via short- or long-loop recycling pathways. Alternatively, ubiquitinated VEGFR2 undergoes 26S proteasome-regulated cleavage of its C-terminus in early endosomes followed by trafficking to late endosomes and lysosomes for terminal degradation. VEGF-A-stimulated VEGFR2 signal transduction promotes increased calcium-dependent plasma membrane translocation of VEGFR1 thus creating a negative feedback loop to attenuate VEGFR2 activity.

cells [105,108–110]. Resting VEGFR2 is distributed between the plasma membrane (~40%) and an internal early endosomal pool (~60%), with constitutive recycling between the two compartments [108,111,112]. Recent work has revealed requirement for syntaxin 6 [109] and the kinesin motor protein KIF13B (kinesin family member 13B) [113] in biosynthetic VEGFR2 trafficking through the Golgi apparatus *en route* to the plasma membrane. Resting VEGFR2 undergoes a relatively fast rate of ligand-independent, constitutive internalization [111,114] which does not require tyrosine kinase activity [108]. Phosphorylation of residues Tyr¹⁰⁵⁴ and Tyr¹⁰⁵⁹ is required for clathrin-dependent internalization of activated VEGFR2 [115]. Chaperone proteins such as HSP70 (heat shock protein 70) have been linked to VEGFR2 ubiquitination and trafficking [116]. HSP70 is associated with VEGFR2 degradation following clathrin-mediated endocytosis. In contrast, HSP90 stabilizes VEGFR2 levels [116]. Thus, the HSP70–HSP90 axis is essential for regulating VEGFR2 homeostasis. Another chaperone protein involved in VEGFR2 stabilization is PDCL3 (phosducin-like 3). Receptor ubiquitination and degrad-

ation is inhibited by PDCL3 binding to the juxtamembrane domain of VEGFR2 thus increasing VEGF-A-stimulated tyrosine phosphorylation [117].

VEGF-A-activated VEGFR2 undergoes endocytosis and targeting for either recycling or degradation [118] (Figure 3). VEGF-A stimulation promotes ~40%–60% degradation of plasma membrane and endosomal VEGFR2 pools [111]. Ligand binding causes a redistribution of VEGFR2 from early to late endosomes depending upon VEGF-A concentration and duration of stimulation; nonetheless, a significant early endosomal pool of VEGFR2 is maintained [111]. It has been proposed that the small Rab (Ras-associated protein) GTPase family members, Rab5a and Rab7a, have regulatory roles in VEGFR2 trafficking and signal transduction in early and late endosomes respectively [119,120] (Figure 3). Following VEGF-A stimulation, phosphorylated and ubiquitinated VEGFR2 is transported to early endosomes after recognition by the ubiquitin-linked receptor complex, ESCRT-0 (endosomal sorting complex required for transport) [121]. Early endosomal localization of VEGFR2 is essential for maximal activation of Akt and ERK1/2 signal

transduction pathways [122,123]. In contrast, p38 MAPK signal transduction is linked to cell surface VEGFR2 [31,114,124].

Recycling of activated VEGFR2 occurs through Rab4a- or Rab11a-positive endosomes and follows a short loop (Rab4a) or long loop (Rab11a) pathway [112,125] (Figure 3). Long loop recycling occurs in co-ordination with NRP1 trafficking following transition from Rab4a-positive vesicles. Rab4a–Rab11a transition is co-ordinated by interaction between the C-terminal PDZ-binding motif of synectin, myosin VI and the NRP-1 C-terminal motif, SEA (serine-glutamic acid-alanine) [125–128]. Receptor recycling via Rab11a-positive endosomes is VEGF-A isoform-dependent. For example, VEGF-A_{165b} isoform is unable to bind NRP1 and fails to promote Rab11a-dependent recycling [125].

Internalized VEGFR2 continues to signal from multiple cellular compartments until it is committed for recycling or degradation [129]. Internalized VEGFR2 is directed for lysosomal degradation as a result of ubiquitination by E3 ligases c-Cbl (Cbl proto-oncogene E3 ubiquitin protein ligase) or β -TrCP1 (β -Transducin repeat containing E3 ubiquitin protein ligase) [106,130,131]. VEGF-A-stimulated ubiquitination or activation of non-classical PKC isozymes promotes increased trafficking and proteolysis of VEGFR2 in the endosome–lysosome system [88,119,130,132]. VEGFR2 proteolysis is tightly regulated; at least two distinct proteolytic steps have been postulated for processing within the endosome-lysosome system. A 26S proteasome-regulated step is associated with early endosomes and cleavage of the C-terminal domain prior to lysosomal processing of the extracellular/luminal domain [88,130] (Figure 3). Proteasome-mediated VEGFR2 proteolysis regulates VEGFR2 signal transduction through the Akt, eNOS and MAPK pathways [130].

DRUGS AND DISEASE

Pathological angiogenesis is associated with multiple diseases. Neurodegenerative disorders, pulmonary hypertension and ischaemic events are associated with inadequate angiogenesis. In contrast, excessive angiogenesis occurs in disorders characterized by abnormal vascular growth and remodelling such as cancer, infectious and inflammatory diseases and AMD [133]. Anti-angiogenic therapy has been targeted towards members of the VEGF family and associated VEGFRs due to their essential role in angiogenesis [134] (Figure 4). Bevacizumab (Avastin) is a humanized monoclonal antibody to VEGF-A approved to treat RCC (renal cell carcinoma), metastatic colorectal cancer, metastatic breast cancer, advanced non-squamous, non-small cell lung cancer and recurrent glioblastoma multiforme [135]. Aflibercept (Zaltrap, VEGF Trap-Eye) is a recombinant fusion protein consisting of the extracellular VEGF-A-binding domains of VEGFR1 and VEGFR2 fused to an Fc domain. This new anti-angiogenic molecule acts as a decoy receptor to block VEGF-A, VEGF-B and PlGF activity and has been approved for the treatment of metastatic RCC [136] (Figure 4).

TKIs (tyrosine kinase inhibitors) constitute another class of anti-angiogenic drugs approved for cancer therapy. These inhibitors disrupt VEGFR1 and/or VEGFR2 signal transduction and often interfere with the activity of other receptor tyrosine kinases such as FGF (fibroblast growth factor) and PDGF receptors [137,138]. The most successful VEGF-related therapies which provide greatest improvement in progression-free survival in cancer patients include Sorafenib and Sunitinib [139] (Figure 4). Sorafenib (Nexavar) is a TKI approved for the treatment of metastatic RCC and hepatocellular carcinoma [140]. The anti-cancer drug Sunitinib (Sutent) is a member of the indolinone family of compounds and is approved to treat RCC and gastrointestinal stromal tumour [140]. Although providing short-term benefits, the activity of these drugs is limited by the introduction of compensatory pathways or resistance mechanisms [138,141]. For example, increased hypoxia as a consequence of VEGF-A inhibition up-regulates pro-angiogenic factors, such as FGFs and PlGF, and promotes recruitment of pro-angiogenic bone marrow-derived cells to induce tumour revascularization [142]. Maintaining the correct balance of inhibition of a select group of receptor tyrosine kinases including VEGFRs and FGF receptors (FGFRs) thus appears clinically important [138,141]. One strategy to combat drug resistance to VEGF inhibitors is the development of multi-targeted TKIs. For example, Nintedanib (Vargatef) is a small molecule multi-target TKI of FGFR, PDGFR and VEGFR used in the treatment of non-small-cell lung cancer [143]. JK-31 is a multi-kinase inhibitor that targets VEGFR2 and CDK1 (cyclin-dependent kinase 1) to simultaneously inhibit pro-angiogenic signal transduction and cell cycle progression in endothelial cells [144]. Another multi-targeted TKI JK-P3 inhibits the intrinsic catalytic activity of VEGFR2 (Figure 4), FGFR1 and FGFR3 [145]. The ability of multi-targeted TKIs to simultaneously inhibit multiple signal transduction pathways enables them to overcome redundant angiogenic factors considered to be a key mechanism underlying resistance to anti-VEGF therapy [146].

The importance of anti-angiogenic drugs in cancer therapy has been highlighted by their use to treat nine distinct solid tumours. Emerging anti-angiogenic agents that selectively inhibit VEGFR2 and VEGFR2-related signalling include Ramucirumab, a fully humanized monoclonal antibody targeting the extracellular domain of VEGFR2 and Apatinib, a small molecule inhibitor of the intracellular domain [140]. Advancement in anti-angiogenic therapies is necessary since they currently prolong survival of responsive patients by months rather than providing long-term progression-free survival and are often only effective in combination with chemotherapy [142].

High levels of VEGF-A found in ocular fluid are associated with AMD, diabetes and ischaemic central retinal vein occlusion [142]. Interestingly, the levels of different VEGF-A isoforms in extracellular fluids could be associated with disease states [17]. In this context, increased expression of the VEGF-A_{165b} isoform is associated with altered risk of prostate cancer and peripheral arterial disease [147,148]. Current treatments that directly target circulating VEGF-A in diseases such as wet AMD include Pegaptanib (Macugen), a pegylated 28-base ribonucleic aptamer that selectively binds the heparin-binding domain of VEGF-A₁₆₅




Figure 4 Therapeutic inhibitors of VEGFR2 signal transduction

Schematic depicting target sites of anti-angiogenic agents that inhibit VEGFR2-mediated signal transduction. VEGF-A_{xxx}; non-specific VEGF-A isoform.

and inhibits bioactivity (Figure 4). Ranibizumab (Lucentis) is a recombinant, humanized anti-VEGF-A antibody fragment derived from Bevacizumab, also approved to treat AMD. Ranibizumab is smaller than Bevacizumab and is thought to deliver more effective retinal penetration [142]. The use of anti-VEGF drugs as monotherapy for the treatment of AMD has proved successful with increased visual acuity experienced by 30% of patients [142].

VEGF-C-induced VEGFR3 activity has been linked to cancer metastasis and disease progression in lung cancer patients [149].

Peptides developed to inhibit the kinase activity of VEGFR3 suppress VEGF-C-mediated cancer cell invasiveness and VEGF-C-induced drug resistance by inhibiting VEGFR3-linked signal transduction [149]. In addition to anti-angiogenic agents, it is desirable that pro-angiogenic drugs will be developed as high impact therapies for cardiovascular diseases.

Current VEGFR therapies target cancer or AMD however future research directions for VEGFR-targeted therapeutics are emerging for other diseases. VEGF plays a crucial protective role in the nervous system. Reduced levels of VEGF and other growth

factors are associated with neurodegenerative diseases. VEGF has been identified as a causative factor in several motor neuron degenerative diseases [150] and epilepsy [151]. VEGF is of particular interest due to its role in cross-talk between the nervous and vascular systems. These multi-tasking effects of VEGF make it a promising therapeutic target.

CONCLUDING REMARKS

The VEGF–VEGFR axis is essential for the maintenance of endothelial and vascular homeostasis and function. A switch to pro- or anti-angiogenic outcomes is associated with diseases ranging from cancer to chronic inflammation and diabetes mellitus. The VEGF–VEGFR system generates a diverse array of responses in different cell types and tissues through VEGF isoform-mediated RTK dimerization and co-receptor recruitment. Emerging research is uncovering essential roles for VEGF–VEGFR signal transduction in non-vascular tissues including the epithelium, brain and immune system. Complexity in the response of cells and tissues to VEGF isoforms highlights the therapeutic potential of manipulating this receptor–ligand axis. A challenge is to target specific VEGF or VEGFR isoforms using antibody, protein or gene-based strategies to shed light on mechanistic principles. Such work could also lay the foundations for more selective drug targeting in disease therapy. VEGF–VEGFR biology is an exciting and expanding area of biology and medicine that is generating new insights into molecular and cellular mechanisms that are being translated into the next generation of therapeutics for major diseases.

FUNDING

This work was supported by the British Heart Foundation [grant number FS/12/20/29462 (to G.A.S.)]; and the Heart Research UK [grant number TRP11/11 (to G.W.F.)].

REFERENCES

- 1 Ponnambalam, S. and Alberghina, M. (2011) Evolution of the VEGF-regulated vascular network from a neural guidance system. *Mol. Neurobiol.* **43**, 192–206 [CrossRef PubMed](#)
- 2 Roskoski, Jr, R. (2007) Vascular endothelial growth factor (VEGF) signaling in tumor progression. *Crit. Rev. Oncol. Hematol.* **62**, 179–213 [CrossRef PubMed](#)
- 3 DiSalvo, J., Bayne, M.L., Conn, G., Kwok, P.W., Trivedi, P.G., Soderman, D.D., Palisi, T.M., Sullivan, K.A. and Thomas, K.A. (1995) Purification and characterization of a naturally occurring vascular endothelial growth factor.placenta growth factor heterodimer. *J. Biol. Chem.* **270**, 7717–7723 [CrossRef PubMed](#)
- 4 Ferrara, N. (2010) Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. *Mol. Biol. Cell* **21**, 687–690 [CrossRef PubMed](#)
- 5 Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoek, A., Harpal, K., Eberhardt, C. et al. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. *Nature* **380**, 435–439 [CrossRef PubMed](#)
- 6 Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K.S., Powell-Braxton, L., Hillan, K.J. and Moore, M.W. (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. *Nature* **380**, 439–442 [CrossRef PubMed](#)
- 7 Carmeliet, P. (2005) Angiogenesis in life, disease and medicine. *Nature* **438**, 932–936 [CrossRef PubMed](#)
- 8 Coultas, L., Chawengsaksophak, K. and Rossant, J. (2005) Endothelial cells and VEGF in vascular development. *Nature* **438**, 937–945 [CrossRef PubMed](#)
- 9 Ferrara, N. and Kerbel, R.S. (2005) Angiogenesis as a therapeutic target. *Nature* **438**, 967–974 [CrossRef PubMed](#)
- 10 Robinson, C.J. and Stringer, S.E. (2001) The splice variants of vascular endothelial growth factor (VEGF) and their receptors. *J. Cell Sci.* **114**, 853–865 [PubMed](#)
- 11 Eswarappa, S.M., Potdar, A.A., Koch, W.J., Fan, Y., Vasu, K., Lindner, D., Willard, B., Graham, L.M., DiCorleto, P.E. and Fox, P.L. (2014) Programmed translational readthrough generates antiangiogenic VEGF-Ax. *Cell* **157**, 1605–1618 [CrossRef PubMed](#)
- 12 Lee, T.Y., Folkman, J. and Javaherian, K. (2010) HSPG-binding peptide corresponding to the exon 6a-encoded domain of VEGF inhibits tumor growth by blocking angiogenesis in murine model. *PLoS One* **5**, e9945 [CrossRef PubMed](#)
- 13 Kawamura, H., Li, X., Goishi, K., van Meeteren, L.A., Jakobsson, L., Cebe-Suarez, S., Shimizu, A., Edholm, D., Ballmer-Hofer, K., Kjellen, L. et al. (2008) Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. *Blood* **112**, 3638–3649 [CrossRef PubMed](#)
- 14 Plouet, J., Moro, F., Bertagnolli, S., Coldeboeuf, N., Mazarguil, H., Clamens, S. and Bayard, F. (1997) Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. *J. Biol. Chem.* **272**, 13390–13396 [CrossRef PubMed](#)
- 15 Jia, H., Jezequel, S., Lohr, M., Shaikh, S., Davis, D., Soker, S., Selwood, D. and Zachary, I. (2001) Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF. *Biochem. Biophys. Res. Commun.* **283**, 164–173 [CrossRef PubMed](#)
- 16 Ancelin, M., Buteau-Lozano, H., Meduri, G., Osborne-Pellegrin, M., Sordello, S., Plouet, J. and Perrot-Appianat, M. (2002) A dynamic shift of VEGF isoforms with a transient and selective progesterone-induced expression of VEGF189 regulates angiogenesis and vascular permeability in human uterus. *Proc. Natl. Acad. Sci. U.S.A.* **99**, 6023–6028 [CrossRef PubMed](#)
- 17 Harper, S.J. and Bates, D.O. (2008) VEGF-A splicing: the key to anti-angiogenic therapeutics? *Nat. Rev. Cancer* **8**, 880–887 [CrossRef PubMed](#)
- 18 Perrin, R.M., Konopatskaya, O., Qiu, Y., Harper, S., Bates, D.O. and Churchill, A.J. (2005) Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. *Diabetologia* **48**, 2422–2427 [CrossRef PubMed](#)
- 19 Varey, A.H., Rennel, E.S., Qiu, Y., Bevan, H.S., Perrin, R.M., Raffy, S., Dixon, A.R., Paraskeva, C., Zaccaro, O., Hassan, A.B. et al. (2008) VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. *Br. J. Cancer* **98**, 1366–1379 [CrossRef PubMed](#)
- 20 Manetti, M., Guiducci, S., Ibba-Manneschi, L. and Matucci-Cerinic, M. (2010) Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. *J. Cell. Mol. Med.* **14**, 1241–1254 [CrossRef PubMed](#)

- 21 Olofsson, B., Pajusola, K., von Euler, G., Chilov, D., Alitalo, K. and Eriksson, U. (1996) Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. *J. Biol. Chem.* **271**, 19310–19317 [CrossRef PubMed](#)
- 22 Grimmond, S., Lagercrantz, J., Drinkwater, C., Silins, G., Townson, S., Pollock, P., Gotley, D., Carson, E., Rakar, S., Nordenskjöld, M. et al. (1996) Cloning and characterization of a novel human gene related to vascular endothelial growth factor. *Genome Res.* **6**, 124–131 [CrossRef PubMed](#)
- 23 Joukov, V., Sorsa, T., Kumar, V., Jeltsch, M., Claesson-Welsh, L., Cao, Y., Saksela, O., Kalkkinen, N. and Alitalo, K. (1997) Proteolytic processing regulates receptor specificity and activity of VEGF-C. *EMBO J.* **16**, 3898–3911 [CrossRef PubMed](#)
- 24 Achen, M.G., Jeltsch, M., Kukkk, E., Makinen, T., Vitali, A., Wilks, A.F., Alitalo, K. and Stacker, S.A. (1998) Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). *Proc. Natl. Acad. Sci. U.S.A.* **95**, 548–553 [CrossRef PubMed](#)
- 25 Stacker, S.A., Stenvers, K., Caesar, C., Vitali, A., Domagala, T., Nice, E., Roufail, S., Simpson, R.J., Moritz, R., Karpanen, T. et al. (1999) Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. *J. Biol. Chem.* **274**, 32127–32136 [CrossRef PubMed](#)
- 26 Baldwin, M.E., Roufail, S., Halford, M.M., Alitalo, K., Stacker, S.A. and Achen, M.G. (2001) Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis. *J. Biol. Chem.* **276**, 44307–44314 [CrossRef PubMed](#)
- 27 Maglione, D., Guerriero, V., Viglietto, G., Ferraro, M.G., Aprelikova, O., Alitalo, K., Del Vecchio, S., Lei, K.J., Chou, J.Y. and Persico, M.G. (1993) Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. *Oncogene* **8**, 925–931 [PubMed](#)
- 28 Maglione, D., Guerriero, V., Viglietto, G., Delli-Bovi, P. and Persico, M.G. (1991) Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. *Proc. Natl. Acad. Sci. U.S.A.* **88**, 9267–9271 [CrossRef PubMed](#)
- 29 Holmes, D.I. and Zachary, I. (2005) The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. *Genome Biol.* **6**, 209 [CrossRef PubMed](#)
- 30 Grunewald, F.S., Prota, A.E., Giese, A. and Ballmer-Hofer, K. (2010) Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. *Biochim. Biophys. Acta* **1804**, 567–580 [CrossRef PubMed](#)
- 31 Sawamiphak, S., Seidel, S., Essmann, C.L., Wilkinson, G.A., Pitulescu, M.E., Acker, T. and Acker-Palmer, A. (2010) Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. *Nature* **465**, 487–491 [CrossRef PubMed](#)
- 32 Errico, M., Riccioni, T., Iyer, S., Pisano, C., Acharya, K.R., Persico, M.G. and De Falco, S. (2004) Identification of placenta growth factor determinants for binding and activation of Flt-1 receptor. *J. Biol. Chem.* **279**, 43929–43939 [CrossRef PubMed](#)
- 33 Olofsson, B., Korpelainen, E., Pepper, M.S., Mandriota, S.J., Aase, K., Kumar, V., Gunji, Y., Jeltsch, M.M., Shibuya, M., Alitalo, K. and Eriksson, U. (1998) Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. *Proc. Natl. Acad. Sci. U.S.A.* **95**, 11709–11714 [CrossRef PubMed](#)
- 34 Makinen, T., Olofsson, B., Karpanen, T., Hellman, U., Soker, S., Klagsbrun, M., Eriksson, U. and Alitalo, K. (1999) Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. *J. Biol. Chem.* **274**, 21217–21222 [CrossRef PubMed](#)
- 35 Takahashi, H. and Shibuya, M. (2005) The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. *Clin. Sci.* **109**, 227–241 [CrossRef PubMed](#)
- 36 Koch, S., Tugues, S., Li, X., Gualandi, L. and Claesson-Welsh, L. (2011) Signal transduction by vascular endothelial growth factor receptors. *Biochem. J.* **437**, 169–183 [CrossRef PubMed](#)
- 37 Pan, Q., Chathery, Y., Wu, Y., Rathore, N., Tong, R.K., Peale, F., Bagri, A., Tessier-Lavigne, M., Koch, A.W. and Watts, R.J. (2007) Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. *J. Biol. Chem.* **282**, 24049–24056 [CrossRef PubMed](#)
- 38 Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernelle, V., De Mol, M., Wu, Y., Bono, F., Devy, L., Beck, H. et al. (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. *Nat. Med.* **7**, 575–583 [CrossRef PubMed](#)
- 39 Tarallo, V., Vesci, L., Capasso, O., Esposito, M.T., Riccioni, T., Pastore, L., Orlandi, A., Pisano, C. and De Falco, S. (2010) A placental growth factor variant unable to recognize vascular endothelial growth factor (VEGF) receptor-1 inhibits VEGF-dependent tumor angiogenesis via heterodimerization. *Cancer Res.* **70**, 1804–1813 [CrossRef PubMed](#)
- 40 Koch, S. and Claesson-Welsh, L. (2012) Signal transduction by vascular endothelial growth factor receptors. *Cold Spring Harb. Perspect. Med.* **2**, a006502 [CrossRef PubMed](#)
- 41 Hagberg, C.E., Falkevall, A., Wang, X., Larsson, E., Huusko, J., Nilsson, I., van Meeteren, L.A., Samen, E., Lu, L., Vanwildemeersch, M. et al. (2010) Vascular endothelial growth factor B controls endothelial fatty acid uptake. *Nature* **464**, 917–921 [CrossRef PubMed](#)
- 42 Li, X., Tjwa, M., Van Hove, I., Enholm, B., Neven, E., Paavonen, K., Jeltsch, M., Juan, T.D., Sievers, R.E., Chorianopoulos, E. et al. (2008) Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. *Arterioscler. Thromb. Vasc. Biol.* **28**, 1614–1620 [CrossRef PubMed](#)
- 43 Kendall, R.L. and Thomas, K.A. (1993) Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. *Proc. Natl. Acad. Sci. U.S.A.* **90**, 10705–10709 [CrossRef PubMed](#)
- 44 Devries, C., Escobedo, J.A., Ueno, H., Houck, K., Ferrara, N. and Williams, L.T. (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth-factor. *Science* **255**, 989–991 [CrossRef PubMed](#)
- 45 Waltenberger, J., Claessonwelsh, L., Siegbahn, A., Shibuya, M. and Heldin, C.H. (1994) Different signal-transduction properties of KDR and Flt1, 2 receptors for vascular endothelial growth-factor. *J. Biol. Chem.* **269**, 26988–26995 [PubMed](#)
- 46 Gille, H., Kowalski, J., Yu, L., Chen, H., Pisabarro, M.T., Davis-Smyth, T. and Ferrara, N. (2000) A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3'-kinase activation and endothelial cell migration. *EMBO J.* **19**, 4064–4073 [CrossRef PubMed](#)
- 47 Meyer, R.D., Mohammadi, M. and Rahimi, N. (2006) A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1. *J. Biol. Chem.* **281**, 867–875 [CrossRef PubMed](#)
- 48 Ito, N., Wernstedt, C., Engstrom, U. and Claesson-Welsh, L. (1998) Identification of vascular endothelial growth factor receptor-1 tyrosine phosphorylation sites and binding of SH2 domain-containing molecules. *J. Biol. Chem.* **273**, 23410–23418 [CrossRef PubMed](#)
- 49 Fong, G.H., Rossant, J., Gertsenstein, M. and Breitman, M.L. (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. *Nature* **376**, 66–70 [CrossRef PubMed](#)
- 50 Shibuya, M. (2001) Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. *Cell Struct. Funct.* **26**, 25–35 [CrossRef PubMed](#)



- 51 Olsson, A.K., Dimberg, A., Kreuger, J. and Claesson-Welsh, L. (2006) VEGF receptor signalling - in control of vascular function. *Nat. Rev. Mol. Cell Biol.* **7**, 359–371 [CrossRef PubMed](#)
- 52 Rahimi, N., Golde, T.E. and Meyer, R.D. (2009) Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells. *Cancer Res.* **69**, 2607–2614 [CrossRef PubMed](#)
- 53 Cai, J., Chen, Z., Ruan, Q., Han, S., Liu, L., Qi, X., Boye, S.L., Hauswirth, W.W., Grant, M.B. and Boulton, M.E. (2011) gamma-Secretase and presenilin mediate cleavage and phosphorylation of vascular endothelial growth factor receptor-1. *J. Biol. Chem.* **286**, 42514–42523 [CrossRef PubMed](#)
- 54 Kendall, R.L., Wang, G., DiSalvo, J. and Thomas, K.A. (1994) Specificity of vascular endothelial cell growth factor receptor ligand binding domains. *Biochem. Biophys. Res. Commun.* **201**, 326–330 [CrossRef PubMed](#)
- 55 Hiratsuka, S., Maru, Y., Okada, A., Seiki, M., Noda, T. and Shibuya, M. (2001) Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. *Cancer Res.* **61**, 1207–1213 [PubMed](#)
- 56 Takahashi, T. and Shibuya, M. (1997) The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts. *Oncogene* **14**, 2079–2089 [CrossRef PubMed](#)
- 57 Albuquerque, R.J., Hayashi, T., Cho, W.G., Kleinman, M.E., Dridi, S., Takeda, A., Baffi, J.Z., Yamada, K., Kaneko, H., Green, M.G. et al. (2009) Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. *Nat. Med.* **15**, 1023–1030 [CrossRef PubMed](#)
- 58 Shalaby, F., Rossant, J., Yamaguchi, T.P., Gertsenstein, M., Wu, X.F., Breitman, M.L. and Schuh, A.C. (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. *Nature* **376**, 62–66 [CrossRef PubMed](#)
- 59 Keyt, B.A., Berleau, L.T., Nguyen, H.V., Chen, H., Heinsohn, H., Vandlen, R. and Ferrara, N. (1996) The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. *J. Biol. Chem.* **271**, 7788–7795 [CrossRef PubMed](#)
- 60 Millauer, B., Witzmann-Voos, S., Schnurch, H., Martinez, R., Moller, N.P., Risau, W. and Ullrich, A. (1993) High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. *Cell* **72**, 835–846 [CrossRef PubMed](#)
- 61 Vaisman, N., Gospodarowicz, D. and Neufeld, G. (1990) Characterization of the receptors for vascular endothelial growth factor. *J. Biol. Chem.* **265**, 19461–19466 [PubMed](#)
- 62 Quinn, T.P., Peters, K.G., Devries, C., Ferrara, N. and Williams, L.T. (1993) Fetal liver kinase-1 is a receptor for vascular endothelial growth-factor and is selectively expressed in vascular endothelium. *Proc. Natl. Acad. Sci. U.S.A.* **90**, 7533–7537 [CrossRef PubMed](#)
- 63 Eichmann, A., Corbel, C., Nataf, V., Vaigot, P., Breant, C. and Le Douarin, N.M. (1997) Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2. *Proc. Natl. Acad. Sci. U.S.A.* **94**, 5141–5146 [CrossRef PubMed](#)
- 64 Kanno, S., Oda, N., Abe, M., Terai, Y., Ito, M., Shitara, K., Tabayashi, K., Shibuya, M. and Sato, Y. (2000) Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. *Oncogene* **19**, 2138–2146 [CrossRef PubMed](#)
- 65 Pajusola, K., Aprelikova, O., Armstrong, E., Morris, S. and Alitalo, K. (1993) Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts. *Oncogene* **8**, 2931–2937 [PubMed](#)
- 66 Galland, F., Karamysheva, A., Pebusque, M.J., Borg, J.P., Rottapel, R., Dubreuil, P., Rosnet, O. and Birnbaum, D. (1993) The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor. *Oncogene* **8**, 1233–1240 [PubMed](#)
- 67 Pajusola, K., Aprelikova, O., Korhonen, J., Kaipainen, A., Pertovaara, L., Alitalo, R. and Alitalo, K. (1992) FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. *Cancer Res.* **52**, 5738–5743 [PubMed](#)
- 68 Hughes, D.C. (2001) Alternative splicing of the human VEGFR-3/FLT4 gene as a consequence of an integrated human endogenous retrovirus. *J. Mol. Evol.* **53**, 77–79 [CrossRef PubMed](#)
- 69 Dixelius, J., Makinen, T., Wirzenius, M., Karkkainen, M.J., Wernstedt, C., Alitalo, K. and Claesson-Welsh, L. (2003) Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. *J. Biol. Chem.* **278**, 40973–40979 [CrossRef PubMed](#)
- 70 Dumont, D.J., Jussila, L., Taipale, J., Lymboussaki, A., Mustonen, T., Pajusola, K., Breitman, M. and Alitalo, K. (1998) Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. *Science* **282**, 946–949 [CrossRef PubMed](#)
- 71 Carmeliet, P., De Smet, F., Loges, S. and Mazzone, M. (2009) Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. *Nat. Rev. Clin. Oncol.* **6**, 315–326 [CrossRef PubMed](#)
- 72 Zhang, L., Zhou, F., Han, W., Shen, B., Luo, J., Shibuya, M. and He, Y. (2010) VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis. *Cell Res.* **20**, 1319–1331 [CrossRef PubMed](#)
- 73 Irrthum, A., Karkkainen, M.J., Devriendt, K., Alitalo, K. and Vikkula, M. (2000) Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. *Am. J. Hum. Genet.* **67**, 295–301 [CrossRef PubMed](#)
- 74 Ruiz de Almodovar, C., Lambrechts, D., Mazzone, M. and Carmeliet, P. (2009) Role and therapeutic potential of VEGF in the nervous system. *Physiol. Rev.* **89**, 607–648 [CrossRef PubMed](#)
- 75 Eichmann, A. and Simons, M. (2012) VEGF signaling inside vascular endothelial cells and beyond. *Curr. Opin. Cell Biol.* **24**, 188–193 [CrossRef PubMed](#)
- 76 Lee, S., Chen, T.T., Barber, C.L., Jordan, M.C., Murdock, J., Desai, S., Ferrara, N., Nagy, A., Roos, K.P. and Iruela-Arispe, M.L. (2007) Autocrine VEGF signaling is required for vascular homeostasis. *Cell* **130**, 691–703 [CrossRef PubMed](#)
- 77 Nilsson, I., Bahram, F., Li, X., Gualandi, L., Koch, S., Jarvius, M., Soderberg, O., Anisimov, A., Kholova, I., Pytowski, B. et al. (2010) VEGF receptor 2/-3 heterodimers detected *in situ* by proximity ligation on angiogenic sprouts. *EMBO J.* **29**, 1377–1388 [CrossRef PubMed](#)
- 78 Stuttfeld, E. and Ballmer-Hofer, K. (2009) Structure and function of VEGF receptors. *IUBMB Life* **61**, 915–922 [CrossRef PubMed](#)
- 79 Kappert, K., Peters, K.G., Bohmer, F.D. and Ostman, A. (2005) Tyrosine phosphatases in vessel wall signaling. *Cardiovasc. Res.* **65**, 587–598 [CrossRef PubMed](#)
- 80 Cunningham, S.A., Arrate, M.P., Brock, T.A. and Waxham, M.N. (1997) Interactions of FLT-1 and KDR with phospholipase C gamma: identification of the phosphotyrosine binding sites. *Biochem. Biophys. Res. Commun.* **240**, 635–639 [CrossRef PubMed](#)
- 81 Yu, Y., Hulmes, J.D., Herley, M.T., Whitney, R.G., Crabb, J.W. and Sato, J.D. (2001) Direct identification of a major autophosphorylation site on vascular endothelial growth factor receptor Flt-1 that mediates phosphatidylinositol 3'-kinase binding. *Biochem. J.* **358**, 465–472 [CrossRef PubMed](#)

- 82 Wiesmann, C., Fuh, G., Christinger, H.W., Eigenbrot, C., Wells, J.A. and de Vos, A.M. (1997) Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor. *Cell* **91**, 695–704 [CrossRef PubMed](#)
- 83 Autiero, M., Waltenberger, J., Communi, D., Kranz, A., Moons, L., Lambrechts, D., Kroll, J., Plaisance, S., De Mol, M., Bono, F. et al. (2003) Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. *Nat. Med.* **9**, 936–943 [CrossRef PubMed](#)
- 84 Mac Gabhann, F. and Popel, A.S. (2007) Dimerization of VEGF receptors and implications for signal transduction: a computational study. *Biophys. Chem.* **128**, 125–139 [CrossRef PubMed](#)
- 85 Shibuya, M. (2014) VEGF-VEGFR signals in health and disease. *Biomol. Ther.* **22**, 1–9 [CrossRef](#)
- 86 Shibuya, M. (2006) Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. *Angiogenesis* **9**, 225–230 [CrossRef PubMed](#)
- 87 Wang, F., Yamauchi, M., Muramatsu, M., Osawa, T., Tsuchida, R. and Shibuya, M. (2011) RACK1 regulates VEGF/Flt1-mediated cell migration via activation of a PI3K/Akt pathway. *J. Biol. Chem.* **286**, 9097–9106 [CrossRef PubMed](#)
- 88 Ewan, L.C., Jopling, H.M., Jia, H., Mittar, S., Bagherzadeh, A., Howell, G.J., Walker, J.H., Zachary, I.C. and Ponnambalam, S. (2006) Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells. *Traffic* **7**, 1270–1282 [CrossRef PubMed](#)
- 89 Cai, J., Ahmad, S., Jiang, W.G., Huang, J., Kontos, C.D., Boulton, M. and Ahmed, A. (2003) Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells. *Diabetes* **52**, 2959–2968 [CrossRef PubMed](#)
- 90 Jiang, B.H. and Liu, L.Z. (2009) PI3K/PTEN signaling in angiogenesis and tumorigenesis. *Adv. Cancer Res.* **102**, 19–65 [CrossRef PubMed](#)
- 91 Tchaikovski, V., Fellbrich, G. and Waltenberger, J. (2008) The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytes. *Arterioscler. Thromb. Vasc. Biol.* **28**, 322–328 [CrossRef PubMed](#)
- 92 Matsumoto, T., Bohman, S., Dixelius, J., Berge, T., Dimberg, A., Magnusson, P., Wang, L., Wikner, C., Qi, J.H., Wernstedt, C. et al. (2005) VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSA1 in tumor angiogenesis. *EMBO J.* **24**, 2342–2353 [CrossRef PubMed](#)
- 93 Takahashi, T., Yamaguchi, S., Chida, K. and Shibuya, M. (2001) A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-γ and DNA synthesis in vascular endothelial cells. *EMBO J.* **20**, 2768–2778 [CrossRef PubMed](#)
- 94 Raikwar, N.S., Liu, K.Z. and Thomas, C.P. (2013) Protein kinase C regulates FLT1 abundance and stimulates its cleavage in vascular endothelial cells with the release of a soluble PlGF/VEGF antagonist. *Exp. Cell Res.* **319**, 2578–2587 [CrossRef PubMed](#)
- 95 Fearnley, G.W., Odell, A.F., Latham, A.M., Mughal, N.A., Bruns, A.F., Burgoyne, N.J., Homer-Vanniasinkam, S., Zachary, I.C., Hollstein, M.C., Wheatcroft, S.B. and Ponnambalam, S. (2014) VEGF-A isoforms differentially regulate ATF-2-dependent VCAM-1 gene expression and endothelial-leukocyte interactions. *Mol. Biol. Cell* **25**, 2509–2521 [CrossRef PubMed](#)
- 96 Holmqvist, K., Cross, M., Riley, D. and Welsh, M. (2003) The Shb adaptor protein causes Src-dependent cell spreading and activation of focal adhesion kinase in murine brain endothelial cells. *Cell Signal.* **15**, 171–179 [CrossRef PubMed](#)
- 97 Lamalice, L., Houle, F. and Huot, J. (2006) Phosphorylation of Tyr1214 within VEGFR-2 triggers the recruitment of Nck and activation of Fyn leading to SAPK2/p38 activation and endothelial cell migration in response to VEGF. *J. Biol. Chem.* **281**, 34009–34020 [CrossRef PubMed](#)
- 98 Datta, S.R., Brunet, A. and Greenberg, M.E. (1999) Cellular survival: a play in three acts. *Genes Dev.* **13**, 2905–2927 [CrossRef PubMed](#)
- 99 Hartsough, E.J., Meyer, R.D., Chitalia, V., Jiang, Y., Marquez, V.E., Zhdanova, I.V., Weinberg, J., Costello, C.E. and Rahimi, N. (2013) Lysine methylation promotes VEGFR-2 activation and angiogenesis. *Sci. Signal.* **6**, ra104 [CrossRef PubMed](#)
- 100 Zecchin, A., Pattarini, L., Gutierrez, M.I., Mano, M., Mai, A., Valente, S., Myers, M.P., Pantano, S. and Giacca, M. (2014) Reversible acetylation regulates vascular endothelial growth factor receptor-2 activity. *J. Mol. Cell Biol.* **6**, 116–127 [CrossRef PubMed](#)
- 101 Salameh, A., Galvagni, F., Bardelli, M., Bussolino, F. and Oliviero, S. (2005) Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. *Blood* **106**, 3423–3431 [CrossRef PubMed](#)
- 102 Mäkinen, T., Veikkola, T., Mustjoki, S., Karpanen, T., Catimel, B., Nice, E.C., Wise, L., Mercer, A., Kowalski, H., Kerjaschki, D. et al. (2001) Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. *EMBO J.* **20**, 4762–4773 [CrossRef PubMed](#)
- 103 Deng, Y., Zhang, X. and Simons, M. (2015) Molecular controls of lymphatic VEGFR3 signaling. *Arterioscler. Thromb. Vasc. Biol.* **35**, 421–429 [CrossRef PubMed](#)
- 104 Mittar, S., Ulyatt, C., Howell, G.J., Bruns, A.F., Zachary, I., Walker, J.H. and Ponnambalam, S. (2009) VEGFR1 receptor tyrosine kinase localization to the Golgi apparatus is calcium-dependent. *Exp. Cell Res.* **315**, 877–889 [CrossRef PubMed](#)
- 105 Bruns, A.F., Bao, L., Walker, J.H. and Ponnambalam, S. (2009) VEGF-A-stimulated signalling in endothelial cells via a dual receptor tyrosine kinase system is dependent on co-ordinated trafficking and proteolysis. *Biochem. Soc. Trans.* **37**, 1193–1197 [CrossRef PubMed](#)
- 106 Duval, M., Bedard-Goulet, S., Delisle, C. and Gratton, J.P. (2003) Vascular endothelial growth factor-dependent down-regulation of Flk-1/KDR involves Cbl-mediated ubiquitination - consequences on nitric oxide production from endothelial cells. *J. Biol. Chem.* **278**, 20091–20097 [CrossRef PubMed](#)
- 107 Kobayashi, S., Sawano, A., Nojima, Y., Shibuya, M. and Maru, Y. (2004) The c-Cbl/CD2AP complex regulates VEGF-induced endocytosis and degradation of Flt-1 (VEGFR-1). *FASEB J.* **18**, 929–931 [PubMed](#)
- 108 Jopling, H.M., Howell, G.J., Gamper, N. and Ponnambalam, S. (2011) The VEGFR2 receptor tyrosine kinase undergoes constitutive endosome-to-plasma membrane recycling. *Biochem. Biophys. Res. Commun.* **410**, 170–176 [CrossRef PubMed](#)
- 109 Manickam, V., Tiwari, A., Jung, J.-J., Bhattacharya, R., Goel, A., Mukhopadhyay, D. and Choudhury, A. (2011) Regulation of vascular endothelial growth factor receptor 2 trafficking and angiogenesis by Golgi localized t-SNARE syntaxin 6. *Blood* **117**, 1425–1435 [CrossRef PubMed](#)
- 110 Bhattacharya, R., Kang-Decker, N., Hughes, D.A., Mukherjee, P., Shah, V., McNiven, M.A. and Mukhopadhyay, D. (2005) Regulatory role of dynamin-2 in VEGFR-2/KDR-mediated endothelial signaling. *FASEB J.* **19**, 1692–1694 [PubMed](#)
- 111 Gampel, A., Moss, L., Jones, M.C., Brunton, V., Norman, J.C. and Mellor, H. (2006) VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment. *Blood* **108**, 2624–2631 [CrossRef PubMed](#)



- 112 Jopling, H.M., Odell, A.F., Pellet-Many, C., Latham, A.M., Frankel, P., Sivaprasadarao, A., Walker, J.H., Zachary, I.C. and Ponnambalam, S. (2014) Endosome-to-plasma membrane recycling of VEGFR2 receptor tyrosine kinase regulates endothelial function and blood vessel formation. *Cells* **3**, 363–385 [CrossRef PubMed](#)
- 113 Yamada, K.H., Nakajima, Y., Geyer, M., Wary, K.K., Ushio-Fukai, M., Komarova, Y. and Malik, A.B. (2014) KIF13B regulates angiogenesis through Golgi to plasma membrane trafficking of VEGFR2. *J. Cell Sci.* **127**, 4518–4530 [CrossRef PubMed](#)
- 114 Lampugnani, M.G., Orsenigo, F., Gagliani, M.C., Tacchetti, C. and Dejana, E. (2006) Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. *J. Cell Biol.* **174**, 593–604 [CrossRef PubMed](#)
- 115 Dougher, M. and Terman, B.I. (1999) Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. *Oncogene* **18**, 1619–1627 [CrossRef PubMed](#)
- 116 Bruns, A.F., Yuldasheva, N., Latham, A.M., Bao, L., Pellet-Many, C., Frankel, P., Stephen, S.L., Howell, G.J., Wheatcroft, S.B., Kearney, M.T. et al. (2012) A heat-shock protein axis regulates VEGFR2 proteolysis, blood vessel development and repair. *PLoS One* **7**, e48539 [CrossRef PubMed](#)
- 117 Srinivasan, S., Meyer, R.D., Lugo, R. and Rahimi, N. (2013) Identification of PDCL3 as a novel chaperone protein involved in the generation of functional VEGF receptor 2. *J. Biol. Chem.* **288**, 23171–23181 [CrossRef PubMed](#)
- 118 Miaczynska, M., Pelkmans, L. and Zerial, M. (2004) Not just a sink: endosomes in control of signal transduction. *Curr. Opin. Cell Biol.* **16**, 400–406 [CrossRef PubMed](#)
- 119 Jopling, H.M., Odell, A.F., Hooper, N.M., Zachary, I.C., Walker, J.H. and Ponnambalam, S. (2009) Rab GTPase regulation of VEGFR2 trafficking and signaling in endothelial cells. *Arterioscl. Thromb. Vasc. Biol.* **29**, 1119–1206 [CrossRef](#)
- 120 Rodman, J.S. and Wandinger-Ness, A. (2000) Rab GTPases coordinate endocytosis - commentary. *J. Cell Sci.* **113**, 183–192 [PubMed](#)
- 121 Grabbe, C., Husnjak, K. and Dikic, I. (2011) The spatial and temporal organization of ubiquitin networks. *Nat. Rev. Mol. Cell Biol.* **12**, 295–307 [CrossRef PubMed](#)
- 122 Lanahan, A.A., Hermans, K., Claes, F., Kerley-Hamilton, J.S., Zhuang, Z.W., Giordano, F.J., Carmeliet, P. and Simons, M. (2010) VEGF receptor 2 endocytic trafficking regulates arterial morphogenesis. *Dev. Cell.* **18**, 713–724 [CrossRef PubMed](#)
- 123 Wang, Y., Nakayama, M., Pitulescu, M.E., Schmidt, T.S., Bochenek, M.L., Sakakibara, A., Adams, S., Davy, A., Deutsch, U., Luethi, U. et al. (2010) Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. *Nature* **465**, 483–486 [CrossRef PubMed](#)
- 124 Chen, T.T., Luque, A., Lee, S., Anderson, S.M., Segura, T. and Iruela-Arispe, M.L. (2010) Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells. *J. Cell Biol.* **188**, 595–609 [CrossRef PubMed](#)
- 125 Ballmer-Hofer, K., Andersson, A.E., Ratcliffe, L.E. and Berger, P. (2011) Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal output. *Blood* **118**, 816–826 [CrossRef PubMed](#)
- 126 Cai, H.B. and Reed, R.R. (1999) Cloning and characterization of neuropilin-1-interacting protein: A PSD-95/Dlg/ZO-1 domain-containing protein that interacts with the cytoplasmic domain of neuropilin-1. *J. Neurosci.* **19**, 6519–6527 [PubMed](#)
- 127 Wang, L., Zeng, H.Y., Wang, P., Soker, S. and Mukhopadhyay, D. (2003) Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. *J. Biol. Chem.* **278**, 48848–48860 [CrossRef PubMed](#)
- 128 Chittenden, T.W., Claes, F., Lanahan, A.A., Autiero, M., Palac, R.T., Tkachenko, E.V., Eifenbein, A., de Almodovar, C.R., Dedkov, E., Tomanek, R. et al. (2006) Selective regulation of arterial branching morphogenesis by syndectin. *Dev. Cell* **10**, 783–795 [CrossRef PubMed](#)
- 129 Murdaca, J., Treins, C., Monthouel-Kartmann, M.N., Pontier-Bres, R., Kumar, S., Van Obberghen, E. and Giorgetti-Peraldi, S. (2004) Grb10 prevents Nedd4-mediated vascular endothelial growth factor receptor-2 degradation. *J. Biol. Chem.* **279**, 26754–26761 [CrossRef PubMed](#)
- 130 Bruns, A.F., Herbert, S.P., Odell, A.F., Jopling, H.M., Hooper, N.M., Zachary, I.C., Walker, J.H. and Ponnambalam, S. (2010) Ligand-stimulated VEGFR2 signaling is regulated by co-ordinated trafficking and proteolysis. *Traffic* **11**, 161–174 [CrossRef PubMed](#)
- 131 Meyer, R.D., Srinivasan, S., Singh, A.J., Mahoney, J.E., Gharahassanlou, K.R. and Rahimi, N. (2011) PEST motif serine and tyrosine phosphorylation controls vascular endothelial growth factor receptor 2 stability and downregulation. *Mol. Cell. Biol.* **31**, 2010–2025 [CrossRef PubMed](#)
- 132 Singh, A.J., Meyer, R.D., Band, H. and Rahimi, N. (2005) The carboxyl terminus of VEGFR-2 is required for PKC-mediated down-regulation. *Mol. Biol. Cell* **16**, 2106–2118 [CrossRef PubMed](#)
- 133 Folkman, J. (2007) Angiogenesis: an organizing principle for drug discovery? *Nat. Rev. Drug Discov.* **6**, 273–286 [CrossRef PubMed](#)
- 134 Tugues, S., Koch, S., Gualandi, L., Li, X. and Claesson-Welsh, L. (2011) Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. *Mol. Aspects Med.* **32**, 88–111 [CrossRef PubMed](#)
- 135 Tarallo, V. and De Falco, S. (2015) The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy. *Int. J. Biochem. Cell Biol.* **64**, 185–189 [CrossRef PubMed](#)
- 136 Ciombor, K.K., Berlin, J. and Chan, E. (2013) Aflibercept. *Clin. Cancer Res.* **19**, 1920–1925 [CrossRef PubMed](#)
- 137 Mendel, D.B., Laird, A.D., Xin, X., Louie, S.G., Christensen, J.G., Li, G., Schreck, R.E., Abrams, T.J., Ngai, T.J., Lee, L.B. et al. (2003) *In vivo* antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. *Clin. Cancer Res.* **9**, 327–337 [PubMed](#)
- 138 Hasinoff, B.B. and Patel, D. (2010) The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes *in vitro*. *Toxicol. Appl. Pharmacol.* **249**, 132–139 [CrossRef PubMed](#)
- 139 Jain, R.K., Duda, D.G., Clark, J.W. and Loeffler, J.S. (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. *Nat. Clin. Pract. Oncol.* **3**, 24–40 [CrossRef PubMed](#)
- 140 Fontanella, C., Ongaro, E., Bolzonello, S., Guardascione, M., Fasola, G. and Aprile, G. (2014) Clinical advances in the development of novel VEGFR2 inhibitors. *Ann. Transl. Med.* **2**, 123 [PubMed](#)
- 141 Zhang, S., Cao, Z., Tian, H., Shen, G., Ma, Y., Xie, H., Liu, Y., Zhao, C., Deng, S., Yang, Y. et al. (2011) SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth *in vivo*. *Clin. Cancer Res.* **17**, 4439–4450 [CrossRef PubMed](#)
- 142 Sennino, B. and McDonald, D.M. (2012) Controlling escape from angiogenesis inhibitors. *Nat. Rev. Cancer.* **12**, 699–709 [CrossRef PubMed](#)

- 143 Caglevic, C., Grassi, M., Raez, L., Listi, A., Giallombardo, M., Bustamante, E., Gil-Bazo, I. and Rolfo, C. (2015) Nintedanib in non-small cell lung cancer: from preclinical to approval. *Ther. Adv. Respir. Dis.* **9**, 164–172
[CrossRef PubMed](#)
- 144 Latham, A.M., Kankanala, J., Fearnley, G.W., Gage, M.C., Kearney, M.T., Homer-Vanniasinkam, S., Wheatcroft, S.B., Fishwick, C.W. and Ponnambalam, S. (2014) *In silico* design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesis. *PLoS One* **9**, e110997
[CrossRef PubMed](#)
- 145 Latham, A.M., Bruns, A.F., Kankanala, J., Johnson, A.P., Fishwick, C.W., Homer-Vanniasinkam, S. and Ponnambalam, S. (2012) Indolinones and anilinophthalazines differentially target VEGFA- and basic fibroblast growth factor-mediated responses in primary human endothelial cells. *Br. J. Pharmacol.* **165**, 245–259
[CrossRef PubMed](#)
- 146 Huang, Y. and Carbone, D.P. (2015) Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer. *Biochim. Biophys. Acta* **1855**, 193–201
[PubMed](#)
- 147 Mavrou, A., Brakspear, K., Hamdollah-Zadeh, M., Damodaran, G., Babaei-Jadidi, R., Oxley, J., Gillatt, D.A., Ladomery, M.R., Harper, S.J., Bates, D.O. and Oltean, S. (2014) Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. *Oncogene* **34**, 4311–4319
[CrossRef PubMed](#)
- 148 Kikuchi, R., Nakamura, K., MacLauchlan, S., Ngo, D.T., Shimizu, I., Fuster, J.J., Katanasaka, Y., Yoshida, S., Qiu, Y., Yamaguchi, T.P. et al. (2014) An antiangiogenic isoform of VEGFA contributes to impaired vascularization in peripheral artery disease. *Nat. Med.* **20**, 1464–1471
[CrossRef PubMed](#)
- 149 Chang, Y.W., Su, C.M., Su, Y.H., Ho, Y.S., Lai, H.H., Chen, H.A., Kuo, M.L., Hung, W.C., Chen, Y.W., Wu, C.H. et al. (2014) Novel peptides suppress VEGFR-3 activity and antagonize VEGFR-3-mediated oncogenic effects. *Oncotarget* **5**, 3823–3835
[PubMed](#)
- 150 Ruiz de Almodovar, C., Lambrechts, D., Mazzone, M. and Carmeliet, P. (2009) Role and therapeutic potential of VEGF in the nervous system. *Physiol. Rev.* **89**, 607–648
[CrossRef PubMed](#)
- 151 Morin-Brureau, M., Rigau, V. and Lerner-Natoli, M. (2012) Why and how to target angiogenesis in focal epilepsies. *Epilepsia* **53** (Suppl 6), 64–68
[CrossRef PubMed](#)

Received 23 June 2015/18 August 2015; accepted 18 August 2015

Accepted Manuscript online 18 August 2015, doi 10.1042/BSR20150171
